Eulry F, Mayaudon H, Lechevalier D, Bauduceau B, Ariche L, Ouakil H, Crozes P, Magnin J
Service de Rhumatologie, Hôpital d'Instruction des Armées Bégin, Saint-Mandé.
Presse Med. 1995 Nov 18;24(35):1642-4.
Non-steroid anti-inflammatory drugs and/or gold salts were unsuccessful alone in providing symptom relief in three men with rheumatoid psoriasis. All three were treated with bromocriptine (5 mg/d in 2 doses) after verification of normal baseline and protirelin-stimulation prolactin levels. There was a beneficial effect in nocturnal pain relief, morning stiffness, the Lee and Ritchie scores and biological markers of inflammation. Two of the patients were able to return to regular work occupation after 15 and 45 days. In the third patient, bromocriptine was discontinued due to nausea and dizziness but was reintroduced successfully in fractionated doses after recurrence of the symptomatology. Treatment was continued without secondary adverse effects for 3 to 9 months providing continued symptom relief. Bromocriptine can be an effective adjuvant for the management of rheumatoid psoriasis.
非甾体抗炎药和/或金盐单独使用时，无法缓解三名类风湿性银屑病男性患者的症状。在确认基线和促甲状腺素刺激催乳素水平正常后，这三名患者均接受了溴隐亭治疗（5毫克/天，分两次服用）。在夜间疼痛缓解、晨僵、李氏和里奇评分以及炎症生物标志物方面均有有益效果。两名患者分别在15天和45天后能够恢复正常工作。第三名患者因恶心和头晕停用了溴隐亭，但在症状复发后成功以分次剂量重新引入。治疗持续3至9个月，无继发不良反应，症状持续缓解。溴隐亭可作为类风湿性银屑病治疗的有效辅助药物。
